Concert Pharmaceuticals wins new patents on deuterium-modified compounds

Concert Pharmaceuticals, a clinical stage biotechnology company, has received its first patents from the US Patent and Trademark Office.

These patents relate to specific compounds derived from Concert’s deuterium chemistry platform. The patents specifically claim deuterium analogs of rimonabant and mosapride, respectively. In addition to these patents, Concert has over 100 pending US patent applications and corresponding applications worldwide.

Deuterium is a safe, non-radioactive relative of hydrogen that can be isolated from sea water and has been used extensively in human metabolic and clinical studies. Since deuterium resembles hydrogen, deuterium-containing compounds are expected to preserve the pharmacological activity of their hydrogen analogs.

Roger Tung, president and CEO of Concert Pharmaceuticals, said: The issuance of these patents that claim deuterium-modified analogs of rimonabant and mosapride as novel compositions of matter illustrates the patentability of our deuterium-modified compounds and further validates the value of our approach. We believe these two patents are the first of many that will be granted on compounds derived from our deuterium chemistry platform.

Concert Pharmaceuticals, a clinical stage biotechnology company focused on the application of deuterium chemistry to create novel small molecule drugs.  The Company has a broad research pipeline encompassing many therapeutic areas including renal disease, infectious disease, and cardiovascular disease, among others.